Steven W. Pipe, MD, explores the latest developments in hemophilia A treatments and prophylactic therapies, including extended half-life agents and a groundbreaking bispecific antibody.
Explore the sequelae of nonadherence to prophylactic treatment in hemophilia A and discover strategies for enhancing treatment adherence and overcoming challenges through interdisciplinary collaborations.
Allison Wheeler, MD, delves into the complexities of prophylaxis for mild to moderate hemophilia A cases, exploring a patient-centric approach, situational prophylaxis during high-risk activities, and best practices in mitigating joint bleeds.
Sobi® will present new data at the 17th European Association of Haemophilia and Allied Disorders conference in Frankfurt from 6-9 February 2024. The studies that will be presented support Sobi s.
Understand key factors influencing hemophilia A treatment decisions and explore the impact of prophylactic vs on-demand therapy on efficacy, safety, and patient outcomes, including joint health, bleeding episodes, and quality of life in severe cases.